- Home
- BFST vs HELP Comparison
BFST vs HELP Comparison
Compare BFST & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | HELP |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 862.2M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BFST | HELP |
|---|---|---|
| Price | $32.35 | $8.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $37.05 | ★ $41.56 |
| AVG Volume (30 Days) | 143.3K | ★ 1.4M |
| Earning Date | 10-26-2026 | 11-24-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $10,704,000.00 | N/A |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $6.61 | N/A |
| P/E Ratio | $15.67 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $24.19 | $3.76 |
| 52 Week High | $33.69 | $15.15 |
Technical Indicators
Market Signals| Indicator | BFST | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 38.50 |
| Support Level | $30.86 | $8.20 |
| Resistance Level | $33.69 | $11.74 |
| Average True Range (ATR) | 0.83 | 0.82 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 57.69 | 20.00 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.